Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma

Intratumour Heterogeneity in Urologic Cancers: From Molecular Evidence to Clinical Implications

(2015) Marco Gerlinger et al.   EUROPEAN UROLOGY

Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras

(2015) Pengxiang Li et al.   Cancer Medicine

Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy

(2014) M. H. Voss et al.   CLINICAL CANCER RESEARCH

Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers

(2014) Sakshi Gulati et al.   EUROPEAN UROLOGY

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

(2014) Marco Gerlinger et al.   NATURE GENETICS

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

(2014) C. Bettegowda et al.   Science Translational Medicine

A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer

(2013) T. Powles et al.   ANNALS OF ONCOLOGY

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

(2013) Robert J Motzer et al.   LANCET ONCOLOGY

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

(2013) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Quantifying tumour heterogeneity with CT

(2013) Balaji Ganeshan et al.   CANCER IMAGING

Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma

(2013) Krastan B. Blagoev et al.   Cell Reports

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Probability of Downsizing Primary Tumors of Renal Cell Carcinoma by Targeted Therapies Is Related to Size at Presentation

(2012) Bin K. Kroon et al.   UROLOGY

Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer

(2011) Irfan Kayani et al.   CLINICAL CANCER RESEARCH

The Outcome of Patients Treated with Sunitinib Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer

(2011) Thomas Powles et al.   EUROPEAN UROLOGY

Vascular Endothelial Growth Factor–Targeted Therapies in Advanced Renal Cell Carcinoma

(2011) Laurence Albiges et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

(2011) Brian I Rini et al.   LANCET

A Phase II Study of Presurgical Sunitinib in Patients With Metastatic Clear-cell Renal Carcinoma and the Primary Tumor In Situ

(2011) Axel Bex et al.   UROLOGY

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

(2010) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon

(2009) Elizabeth R. Plimack et al.   CANCER

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL